Lista de obras -

A disease risk index for patients undergoing allogeneic stem cell transplantation ⬇️

artículo científico publicado el 18 de junio de 2012

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities ⬇️

artículo científico publicado el 6 de octubre de 2010

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas

artículo científico publicado en 2010

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects

artículo científico publicado en 2013

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia

artículo científico publicado en 2005

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

artículo científico publicado en 2020

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma

artículo científico publicado en 2016

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

artículo científico publicado en 2007

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation

artículo científico publicado en 2014

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors

artículo científico publicado en 2007

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

artículo científico publicado en 2004

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation

artículo científico publicado en 2005

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies ⬇️

artículo científico publicado el 26 de mayo de 2010

Cord-Blood Transplantation in Patients with Minimal Residual Disease

artículo científico publicado en 2016

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation

artículo científico publicado en 2015

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality

artículo científico publicado en 2017

Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia

artículo científico publicado en 2016

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning

artículo científico publicado en 2007

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation

scientific article published on 08 August 2006

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

artículo científico publicado en 2012

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

artículo científico publicado en 2008

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission

artículo científico publicado en 2013

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation

artículo científico publicado en 2013

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

artículo científico publicado en 2005

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

artículo científico publicado en 2005

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

artículo científico publicado en 2005

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

artículo científico publicado en 2007

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

artículo científico publicado en 2007

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

artículo científico publicado en 2008

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

artículo científico publicado en 2022

Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation

artículo científico publicado en 2008

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy

artículo científico publicado en 2006

Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation

artículo científico publicado en 2008

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

artículo científico publicado en 2008

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

artículo científico publicado en 2011

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation

artículo científico publicado en 2014

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

artículo científico publicado en 2015

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

artículo científico publicado en 2004

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

artículo científico publicado en 2015

Need for routine examination of left ventricular ejection fraction in patients with AML

artículo científico publicado en 2019

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience

artículo científico publicado en 2008

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma

artículo científico publicado en 2007

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma

artículo científico publicado en 2007

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission

artículo científico publicado en 2014

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia

artículo científico publicado en 2007

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease

artículo científico publicado en 2015

Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality

artículo científico publicado en 2018

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

artículo científico publicado en 2014

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources

scientific article published on 28 November 2018

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome

artículo científico publicado en 2014

Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease

artículo científico publicado en 2005

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

artículo científico publicado en 2006

Reduced mortality after allogeneic hematopoietic-cell transplantation

artículo científico publicado en 2010

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation

artículo científico publicado en 2015

Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML

scientific article published on 24 July 2020

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

scientific article published on 03 September 2019

Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation ⬇️

artículo científico publicado el 9 de junio de 2010

Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts

artículo científico publicado en 2009

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts

scientific article published on 21 January 2020

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

artículo científico publicado en 2012

The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation

artículo científico publicado en 2010

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

artículo científico publicado en 2017

Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia

artículo científico publicado en 2005

Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences

artículo científico publicado en 2009

What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?

artículo científico publicado en 2005

Lista de obras de

A disease risk index for patients undergoing allogeneic stem cell transplantation ⬇️

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities ⬇️

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies ⬇️

Cord-Blood Transplantation in Patients with Minimal Residual Disease

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality

Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy

Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

Need for routine examination of left ventricular ejection fraction in patients with AML

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease

Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome

Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

Reduced mortality after allogeneic hematopoietic-cell transplantation

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation

Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation ⬇️

Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia

Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences

What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?